Processa Pharmaceuticals
PCSA
7 hedge funds and large institutions have $101K invested in Processa Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0.19% less ownership
Funds ownership: 0.25% → 0.06% (-0.19%)
22% less funds holding
Funds holding: 9 → 7 (-2)
60% less capital invested
Capital invested by funds: $251K → $101K (-$151K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$33.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$115K |
| 2 |
Two Sigma Investments
New York
|
-$57K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$9.89K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.95K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$246 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $54.7K | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $38.8K | +$33.9K | +689 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $6.72K | -$2.95K | -60 | -33% |
|
4
Wells Fargo
San Francisco,
California
| $345 | -$49 | -1 | -14% |
|
|
MSG
5
Main Street Group
Glen Allen,
Virginia
| $209 | – | – | – |
|
|
AF
6
Allworth Financial
Folsom,
California
| $139 | – | – | – |
|
|
7
Bank of America
Charlotte,
North Carolina
| $47 | -$246 | -5 | -83% |
|
|
MIM
8
Macroview Investment Management
Bethesda,
Maryland
| $3 | – | – | – |
|
|
SM
9
Sabby Management
Miami Beach,
Florida
| – | -$115K | -1,944 | Closed |
|
|
10
Two Sigma Investments
New York
| – | -$57K | -964 | Closed |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$9.89K | -167 | Closed |
|
PCSA Hedge Fund Activity: Q2 2024 in Review
7 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q2 2024, worth a combined $101K — down 60% from $251K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of PCSA and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 0 added.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $33.9K. The largest seller was Sabby Management, exiting entirely with an estimated $115K sold.
- 7 institutional investors held Processa Pharmaceuticals (PCSA) as of Q2 2024, down from 9 in Q1 2024.
- Funds reported $101K of Processa Pharmaceuticals stock for Q2 2024, down 60% quarter-over-quarter.
- 1 fund opened new Processa Pharmaceuticals positions in Q2 2024 and 3 closed out, a net change of -2 holders.
- The largest Processa Pharmaceuticals buyer in Q2 2024 was Geode Capital Management, an estimated $33.9K added.
- The largest Processa Pharmaceuticals seller in Q2 2024 was Sabby Management, an estimated $115K sold.
Based on aggregated 13F filings for Q2 2024.